No Cover Image

Journal article 67 views 45 downloads

Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease

RAJVANSHI SUTARIA, Zi Hong Mok Orcid Logo

Pharmaceutical Science Advances, Volume: 1, Issue: 2, Start page: 100014

Swansea University Authors: RAJVANSHI SUTARIA, Zi Hong Mok Orcid Logo

  • 65723.pdf

    PDF | Version of Record

    This is an open access article under the CC BY-NC-ND license.

    Download (1.91MB)

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remain...

Full description

Published in: Pharmaceutical Science Advances
ISSN: 2773-2169
Published: Elsevier BV 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa65723
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Inflammatory bowel disease (IBD) is a chronic inflammatory illness that causes ongoing bodily inflammation in the gastrointestinal tract. Drug-targeted delivery of aminosalicylates such as mesalazine at the inflammation sites, to treat ulcerative colitis (UC) and Crohn's disease (CD) has remained a difficulty. Current mesalazine formulations, including tablets, suppositories, and enemas, are typically associated with adverse systemic effects. The use of nanocarriers however has opened the possibility of improved local targeting and pharmacokinetics of loaded mesalazine, based on the new physicochemical properties of the drug vehicle. The innovative nanoencapsulation of mesalazine has demonstrated success in targeting inflammatory regions and treating mild to moderate IBD. The use of nanocarriers, such as lipid-based, polymeric, and inorganic nanocarriers, has demonstrated improved overall solubility, absorption, and bioavailability of mesalazine while minimising the side effects associated with their absorption. This review aims to offer an insight into what is currently known about IBD, and the nanotechnological approaches for the improvement of mesalazine therapy for IBD.
Keywords: Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Mesalazine; Nanocarriers
College: Faculty of Medicine, Health and Life Sciences
Funders: Shandong University
Issue: 2
Start Page: 100014